Roundup 2019: Healthcare stocks in neck-to-neck competition
Updated : December 27, 2019 06:18 AM IST
In the last one year, Dr Lal Pathlabs (DLP) has risen 50 percent while its competitor Metropolis Healthcare surged 46 percent since April 15 this year.
In terms of financial earnings and ratios over the recent years, DLP and Metropolis had a neck-to-neck tough fight.
Last month, CLSA published a research report on DLP, retaining the ‘buy’ rating on the stock with the target price increased to Rs 1,800 from Rs 1,330 earlier.
Have you signed up for Primo, our daily newsletter?
It has all the stories and data on the market, business, economy and tech that you need to know.
THANK YOU! You made our day. See you every morning
YOUR EMAIL IS ON ITS WAY. Check your inbox for future updates.
To keep watching CNBC-TV18, India's No. 1 English Business News Channel, call your Cable or DTH Operator and subscribe now for just Rs. 4 per month. You can also subscribe to CNBC-TV18 Prime HD for Re 1/- per month.Find out more